Vaxart
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 109
- Market Cap
- $202M
- Website
- http://www.vaxart.com
- Introduction
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.
Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults
- Conditions
- Seasonal Influenza Preventative Vaccine Pharmacodynamics
- Interventions
- Biological: VXA-A1.1 H1 Tablet Vaccine (small)Biological: VXA-A1.1 H1 Tablet Vaccine (large)
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- Vaxart
- Target Recruit Count
- 8
- Registration Number
- NCT03121339
- Locations
- 🇺🇸
Scintipharma, Inc., Lexington, Kentucky, United States
A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection
- Conditions
- RhinovirusUpper Respiratory Tract Infection
- Interventions
- Drug: VapendavirDrug: Placebo Oral Tablet
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- Vaxart
- Registration Number
- NCT03024177
A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine
- Conditions
- Influenza
- Interventions
- Biological: VXA-A1.1Other: Placebo TabletsBiological: Fluzone®Other: Saline Solution for Placebo IM Injection
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Vaxart
- Target Recruit Count
- 179
- Registration Number
- NCT02918006
- Locations
- 🇺🇸
WCCT Global, Costa Mesa, California, United States
Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine
- Conditions
- Norovirus Gastroenteritis
- Interventions
- Biological: VXA-G1.1-NN (high dose) Oral Vaccine TabletOther: VXA Placebo TabletsBiological: VXA-G1.1-NN (low dose) Oral Vaccine Tablet
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2018-05-31
- Lead Sponsor
- Vaxart
- Target Recruit Count
- 66
- Registration Number
- NCT02868073
- Locations
- 🇺🇸
Celerion, Inc., Lincoln, Nebraska, United States
Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Biological: VXA-RSV-f Tablets (high dose)Other: VXA Placebo TabletsBiological: VXA-RSV-f Tablets (low dose)
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Vaxart
- Target Recruit Count
- 66
- Registration Number
- NCT02830932
- Locations
- 🇺🇸
Optimal Research, Melbourne, Florida, United States
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
- Conditions
- Condyloma
- Interventions
- Drug: AP611074 5% gelDrug: AP611074 matching placebo
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2018-07-20
- Lead Sponsor
- Vaxart
- Target Recruit Count
- 218
- Registration Number
- NCT02724254
- Locations
- 🇦🇷
Anaconda Invesigational Site, Buenos Aires, Argentina
🇷🇸Anaconda Investigational Site, Novi Sad, Serbia
Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults
- Conditions
- Seasonal Influenza B
- Interventions
- Biological: VXA-BYW.10 (High Dose) Oral VaccineBiological: VXA-BYW.10 (Low Dose) Oral VaccineOther: Placebo Tablets
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2018-05-31
- Lead Sponsor
- Vaxart
- Target Recruit Count
- 54
- Registration Number
- NCT02547792
- Locations
- 🇳🇿
CCST, Christchurch, New Zealand
Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum
- Conditions
- Seasonal Influenza
- Interventions
- Biological: VXA-A1.1
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2014-12-10
- Lead Sponsor
- Vaxart
- Target Recruit Count
- 37
- Registration Number
- NCT01761123
- Locations
- 🇺🇸
Scintipharma, Lexington, Kentucky, United States
Immunogenicity of ND1.1 by Delivery Directly to the Ileum
- Conditions
- Avian Influenza
- Interventions
- Biological: ND1.1
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2014-12-10
- Lead Sponsor
- Vaxart
- Target Recruit Count
- 12
- Registration Number
- NCT01698060
- Locations
- 🇺🇸
Scintipharma, Lexington, Kentucky, United States
Safety Study of an Oral Vaccine to Prevent Seasonal Influenza
- Conditions
- Influenza
- Interventions
- Biological: VXA Placebo TabletBiological: VXA-A1.1 Oral Vaccine
- First Posted Date
- 2012-09-19
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Vaxart
- Target Recruit Count
- 61
- Registration Number
- NCT01688297
- Locations
- 🇺🇸
WCCT, Cypress, California, United States